Jazz Pharmaceuticals (JAZZ) Share-based Compensation (2010 - 2026)

Jazz Pharmaceuticals' Share-based Compensation history runs 17 years deep, the most recent figure standing at $74.5 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 10.04% year-over-year to $74.5 million; the TTM figure through Mar 2026 stood at $297.9 million (up 365.43% YoY), while the FY2025 annual figure was $291.1 million, up 404.1% from the prior year.
• Share-based Compensation for Q1 2026 stood at $74.5 million, up from $70.9 million in the prior quarter.
• The five-year high for Share-based Compensation was $150.9 million in Q3 2025, with the low at -$115.0 million in Q4 2022.
• The 5-year median for Share-based Compensation is $56.4 million (2023), against an average of $40.9 million.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation tumbled 395.31% in 2022, then jumped 1669.14% in 2025.
• Jazz Pharmaceuticals' Share-based Compensation stood at -$115.0 million in 2022, then jumped by 146.04% to $52.9 million in 2023, then plunged by 92.43% to $4.0 million in 2024, then surged by 1669.14% to $70.9 million in 2025, then grew by 5.15% to $74.5 million in 2026.
• Business Quant data shows JAZZ's Share-based Compensation at $74.5 million in Q1 2026, $70.9 million in Q4 2025, and $150.9 million in Q3 2025.